First Ten MUSE™ Procedures for GERD Performed in China as Part of CFDA Multi-Center Clinical Study

OMER, Israel, April 27, 2017 — Medigus Ltd. (NASDAQ: MDGS) (TASE: MDGS), a medical device company developing minimally invasive endosurgical tools and a leader in direct visualization technology, today announced that the first ten procedures have been performed as the initial phase of the China Food and Drug Administration, or CFDA, multi-center MUSE™ Clinical Study in China.

"The availability of the MUSE™ procedure in China provides patients with a less invasive option for the long-term treatment of GERD,” said principal investigator, Yunsheng Yang, Director of Gastroenterology Department Clinical center at 301 Hospital and chairman of Chinese Society of Gastroenterology, The General Hospital of People's Liberation Army in Beijing. “The procedure addresses a new hope and solution between drug therapy and surgical procedures."

Procedures for the clinical study, which will include approximately 62 patients, have begun at four centers across China:
• The General Hospital of People’s Liberation Army
• Renji Hospital of Shanghai
• Shanghai General Hospital
• Peking University Third Hospital

Procedures are expected to continue through 2017, with results being reported to the CFDA in 2018 as part of the submission for clearance to sell MUSE™ in China.

“This is yet another milestone in our mission to expand the use of MUSE worldwide,” said Chris Rowland, CEO of Medigus. “We are looking forward to a successful clinical trial in China, which will lead to higher adoption of MUSE in the East Asian market, which has an increasing prevalence of GERD.”

The MUSE system is a single-use flexible transoral stapler that merges the latest advancements in microvisual, ultrasonic and surgical stapling. The device comes equipped with an ultrasonic sight and range finder and a micro ScoutCam™ CMOS camera, which enables a single physician to perform an incisionless transoral fundoplication — the procedure intended to treat the anatomical cause of gastroesophageal reflux disease (GERD).

For more information about the clinical study or to determine if you are eligible for the trial, patients can directly contact participating medical centers.